Chromatograms proved the selectivity of the proposed method. Red line: tissue spiked at the LOQ level; green line: blank tissue. Panel A: SIM and SIMA; panel B: LOV and LOVA. by Ewa Paszkowska (21246702)

Subjects:

A summary of calibration standards (n = 3). by Ewa Paszkowska (21246702)

Subjects:

The observed MRM reactions. by Ewa Paszkowska (21246702)

Subjects:

Intra- and inter-day precision and accuracy. by Ewa Paszkowska (21246702)

Subjects:

Table 1_Elevated CO2 decreases micronutrient Zn but not Fe in vegetables – evidence from a meta-analysis.docx by Xiaolin Wang (303612)

Table 1_Higher oxidative balance score is associated with a decreased risk of infertility: an analysis of NHANES 2013–2020.docx by Mingjun Ma (11518765)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

XRD analysis [17]. by Saleh Ahmed Aldahash (16441937)

The minimal data set 17. by Esete Habtemariam Fenta (9727779)

Cohort characteristics. by Vincent Pey (21433304)

“…</p><p>Results</p><p>Upon initiation of CPB we observed a significant decrease in arterial whole blood redox potential (101.90 mV + /- 11.52 vs. 41.80 mV + /- 10,26; p < 0.0001). …”

Analytical framework and statistical methods. by Na Chen (153323)

“…Our findings reveal significant variations in income insecurity and social protection responses across these groups. the pandemic had a significant impact on household incomes globally, with lower-middle-income countries experiencing the most significant income reductions. …”

Theoretical frameworks of social protection. by Na Chen (153323)

“…Our findings reveal significant variations in income insecurity and social protection responses across these groups. the pandemic had a significant impact on household incomes globally, with lower-middle-income countries experiencing the most significant income reductions. …”

(A) Side image of epoxy resin-made abutment-analog base and prosthesis; (B) Front image of epoxy resin-made abutment-analog base and prosthesis. by Long Li (6555)

<b>The loss of insulin-positive cell clusters precedes the decrease of islet frequency and beta cell area in type 1 diabetes</b> by Denise M. Drotar (21679539)

“…Moreover, changes in endocrine composition also occurred in mAAb+ donors, including a significant decrease in the INS+ islet fraction. These data suggest preferential loss of INS+ small endocrine objects early in type 1 diabetes development.…”

PICOS criteria for the SLR. by Filip Stanicic (17808254)

“…</p><p>MDMA-AT demonstrated significant improvement in BDI-II score compared to PT (19.7-point vs. 10.8-point decrease, respectively; p = 0.003). …”

Study selection criteria. by Filip Stanicic (17808254)

“…</p><p>MDMA-AT demonstrated significant improvement in BDI-II score compared to PT (19.7-point vs. 10.8-point decrease, respectively; p = 0.003). …”

PRISMA flow chart. by Filip Stanicic (17808254)

“…</p><p>MDMA-AT demonstrated significant improvement in BDI-II score compared to PT (19.7-point vs. 10.8-point decrease, respectively; p = 0.003). …”

Comparison before and after the experiment in each group. by Neng Pan (5262032)

Subjects: